Dapagliflozin tablets – new reimbursement prices from September 2025
Dapagliflozin 5mg and 10mg tablets reimbursement prices have decreased following a move from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. More information on the [...]
The post Dapagliflozin tablets – new reimbursement prices from September 2025 appeared first on Community Pharmacy England.
Recent Comments